Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
Creemers JHA, Pawlitzky I, Grosios K, Gileadi U, Middleton MR, Gerritsen WR, Mehra N, Rivoltini L, Walters I, Figdor CG, Ottevanger PB, de Vries IJM. Creemers JHA, et al. Among authors: middleton mr. BMJ Open. 2021 Nov 30;11(11):e050725. doi: 10.1136/bmjopen-2021-050725. BMJ Open. 2021. PMID: 34848513 Free PMC article.
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE. Leijen S, et al. Among authors: middleton mr. Clin Cancer Res. 2012 Sep 1;18(17):4794-805. doi: 10.1158/1078-0432.CCR-12-0868. Epub 2012 Jul 5. Clin Cancer Res. 2012. PMID: 22767668 Clinical Trial.
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR. Eyre TA, et al. Among authors: middleton mr. Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17. Cancer. 2019. PMID: 30332497 Free article. Clinical Trial.
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Sabharwal A, Corrie PG, Midgley RS, Palmer C, Brady J, Mortimer P, Watson AJ, Margison GP, Middleton MR. Sabharwal A, et al. Among authors: middleton mr. Cancer Chemother Pharmacol. 2010 Oct;66(5):829-35. doi: 10.1007/s00280-009-1225-0. Epub 2009 Dec 29. Cancer Chemother Pharmacol. 2010. PMID: 20039040 Clinical Trial.
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR. Khan OA, et al. Among authors: middleton mr. Br J Cancer. 2011 Mar 1;104(5):750-5. doi: 10.1038/bjc.2011.8. Epub 2011 Feb 15. Br J Cancer. 2011. PMID: 21326243 Free PMC article. Clinical Trial.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. Leijen S, et al. Cancer Chemother Pharmacol. 2011 Dec;68(6):1619-28. doi: 10.1007/s00280-011-1732-7. Epub 2011 Sep 28. Cancer Chemother Pharmacol. 2011. PMID: 21953275 Free PMC article. Clinical Trial.
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H 3rd. Bendell J, et al. Among authors: middleton mr. Ann Oncol. 2015 Apr;26(4):804-811. doi: 10.1093/annonc/mdu581. Epub 2015 Jan 7. Ann Oncol. 2015. PMID: 25573533 Free PMC article. Clinical Trial.
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM. Macaulay VM, et al. Among authors: middleton mr. Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1. Clin Cancer Res. 2016. PMID: 26831715 Free PMC article. Clinical Trial.
234 results